Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Tourette Syndrome Treatment Market: By Medical Treatment and Geography
Tourette Syndrome Treatment Market Size was valued at US$ 2.60 billion in 2022 and is poised to grow at a CAGR of 4.4% from 2023-29. Tourette syndrome is one type of neurological disorder characterized by stereotypic, repetitive involuntary movements known as tics. This syndrome usually affects people of age between 2 to 15 years. Tourette syndrome is 4 times more common in males than females. The patients may experience simple ticks including eye blinking, head jerking, eye darting, or nose twitching. Complex ticks include obscene gesturing, hopping, touching or smelling objects, and stepping in a certain pattern. Companies in the global Tourette syndrome management market are actively involved in the R&D activities in the development of new treatment options to treat the syndrome.
Furthermore, collaborations and acquisitions are also the key strategies adopted by the companies to maximize their market share. For instance, Neurocrine's INGREZZA is under phase 2 clinical trials for the treatment of Tourette syndrome. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The Tourette Syndrome Treatment Market report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
Study Period
2024-2030Base Year
2023CAGR
4.4%Largest Market
EuropeFastest Growing Market
North America
Global Tourette syndrome market is mainly driven by the growing incidence of the syndrome and efforts of organizations such as WHO, Center for Disease Control and Prevention (CDC) in increasing awareness related to the disease. For instance, study conducted by CDC in 2012, about 1, 38000 children were diagnosed with the Tourette syndrome in 2011. In addition, ongoing clinical development stage molecules to treat the Tourette syndrome such as SNC -102, ABX1431 and increase in research funding are expected to boost the market over the forecast period. However, cost of therapy and side effects of drugs are expected to hamper the market growth over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 2.60 billion |
Market CAGR |
4.4% |
By Medical Treatment |
|
By Region |
|
Download Free Sample Report
The global tourette syndrome treatment market size was valued at US$ 2.60 billion in 2022
The tourette syndrome treatment market key players are Novartis AG (Switzerland) Neurocrine Biosciences, Inc. (U.S.) Otsuka Pharmaceutical Co., Ltd. (Japan) Apotex, Inc. (Canada) Teva Pharmaceutical Industries Ltd. (Israel) Cadila Healthcare (India) Janssen and Janssen Services Inc. (U.S.) Torrent Pharmaceuticals Limited. (India) Eli Lilly and Company (U.S.)
The tourette syndrome treatment market drivers are increasing cases of tourette syndrome
1.Executive Summary |
2.Global Tourette Syndrome Treatment Market Introduction |
2.1.Global Tourette Syndrome Treatment Market - Taxonomy |
2.2.Global Tourette Syndrome Treatment Market - Definitions |
2.2.1. By Medical Treatment |
2.2.2. By Region |
3.Global Tourette Syndrome Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Tourette Syndrome Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Tourette Syndrome Treatment Market By Medical Treatment, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Pimozide |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Haloperidol |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Tourette Syndrome Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. North America |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Europe |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Asia Pacific (APAC) |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Middle East and Africa (MEA) |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Latin America |
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.North America Tourette Syndrome Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Medical Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
7.1.1.Pimozide |
7.1.2.Haloperidol |
7.1.3.Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
7.2. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
7.2.1.United States of America (USA) |
7.2.2.Canada |
8.Europe Tourette Syndrome Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Medical Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Pimozide |
8.1.2.Haloperidol |
8.1.3.Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
8.2. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Germany |
8.2.2.France |
8.2.3.Italy |
8.2.4.United Kingdom (UK) |
8.2.5.Spain |
9.Asia Pacific (APAC) Tourette Syndrome Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Medical Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Pimozide |
9.1.2.Haloperidol |
9.1.3.Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
9.2. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.China |
9.2.2.India |
9.2.3.Australia and New Zealand (ANZ) |
9.2.4.Japan |
9.2.5.Rest of APAC |
10.Middle East and Africa (MEA) Tourette Syndrome Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Medical Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Pimozide |
10.1.2.Haloperidol |
10.1.3.Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
10.2. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.GCC Countries |
10.2.2.South Africa |
10.2.3.Rest of MEA |
11.Latin America Tourette Syndrome Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Medical Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Pimozide |
11.1.2.Haloperidol |
11.1.3.Medication (Pimozide, Haloperidol, Serotonin Reuptake Inhibitors, ADHD Drugs) |
11.2. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Brazil |
11.2.2.Mexico |
11.2.3.Rest of LA |
12. Competition Landscape |
12.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
12.2.1.Novartis AG (Switzerland) |
12.2.2.Neurocrine Biosciences, Inc. (U.S.) |
12.2.3.Otsuka Pharmaceutical Co., Ltd. (Japan) |
12.2.4.Apotex, Inc. (Canada) |
12.2.5.Teva Pharmaceutical Industries Ltd. (Israel) |
12.2.6.Cadila Healthcare (India) |
12.2.7.Torrent Pharmaceuticals Limited. (India) |
12.2.8.Eli Lilly and Company (U.S.) |
13. Research Methodology |
14. Appendix and Abbreviations |
Key Market Players